BRPI0915417B8 - derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina - Google Patents

derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina

Info

Publication number
BRPI0915417B8
BRPI0915417B8 BRPI0915417A BRPI0915417A BRPI0915417B8 BR PI0915417 B8 BRPI0915417 B8 BR PI0915417B8 BR PI0915417 A BRPI0915417 A BR PI0915417A BR PI0915417 A BRPI0915417 A BR PI0915417A BR PI0915417 B8 BRPI0915417 B8 BR PI0915417B8
Authority
BR
Brazil
Prior art keywords
triazolo
pyrimidin
benzyl
pyridazine derivatives
inhibitors
Prior art date
Application number
BRPI0915417A
Other languages
English (en)
Inventor
Blaukat Andree
Dorsch Dieter
Stieber Frank
Schadt Oliver
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0915417A2 publication Critical patent/BRPI0915417A2/pt
Publication of BRPI0915417B1 publication Critical patent/BRPI0915417B1/pt
Publication of BRPI0915417B8 publication Critical patent/BRPI0915417B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo[4,3-b]piridazina como inibidores da met quinase. a presente invenção refere-se aos compostos da fórmula (i), na qual r1,r2,r3,r4 são, cada um, como definidos na reivindicação 1, são inibidores das tirosina quinases, especialmente da met quinase, e podem ser usados para o tratamento de tumores, entre outros usos.
BRPI0915417A 2008-06-18 2009-05-25 derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina BRPI0915417B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008028905A DE102008028905A1 (de) 2008-06-18 2008-06-18 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008028905.1 2008-06-18
PCT/EP2009/003675 WO2009152920A1 (de) 2008-06-18 2009-05-25 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazin-derivative als met-kinase inhibitoren

Publications (3)

Publication Number Publication Date
BRPI0915417A2 BRPI0915417A2 (pt) 2015-11-03
BRPI0915417B1 BRPI0915417B1 (pt) 2020-02-11
BRPI0915417B8 true BRPI0915417B8 (pt) 2021-05-25

Family

ID=40973097

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915417A BRPI0915417B8 (pt) 2008-06-18 2009-05-25 derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina

Country Status (19)

Country Link
US (1) US8497266B2 (pt)
EP (1) EP2285811B1 (pt)
JP (1) JP5662311B2 (pt)
KR (1) KR101661777B1 (pt)
CN (1) CN102066378B (pt)
AR (1) AR072860A1 (pt)
AU (1) AU2009259764B2 (pt)
BR (1) BRPI0915417B8 (pt)
CA (1) CA2728194C (pt)
DE (1) DE102008028905A1 (pt)
DK (1) DK2285811T3 (pt)
EA (1) EA019534B1 (pt)
ES (1) ES2400117T3 (pt)
IL (1) IL210063A (pt)
MX (1) MX2010013649A (pt)
PL (1) PL2285811T3 (pt)
PT (1) PT2285811E (pt)
WO (1) WO2009152920A1 (pt)
ZA (1) ZA201100437B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
US8586599B2 (en) 2008-12-22 2013-11-19 Merck Patent Gmbh Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102008062825A1 (de) * 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
CN105339370B (zh) * 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11180480B2 (en) 2017-10-17 2021-11-23 Sensorion Synthesis of 4-aminopyrimidine compounds

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
CN100491349C (zh) 2001-08-10 2009-05-27 盐野义制药株式会社 抗病毒药
EP1463509A1 (en) 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
BRPI0412003A (pt) 2003-07-02 2006-08-15 Sugen Inc arilmetil triazol e imidazopirazinas como inibidores de c-met
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070015771A1 (en) * 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) * 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
AU2006275270A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
MX2008008277A (es) * 2005-12-21 2009-03-04 Janssen Pharmaceutica Nv Triazolopiridazinas como moduladores de tirosina cinasa.
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
PT2081937E (pt) * 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) * 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009050197A2 (en) 2007-10-16 2009-04-23 Novartis Ag Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
JP5395808B2 (ja) 2007-12-21 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CL2008003799A1 (es) 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
JP5498396B2 (ja) 2007-12-21 2014-05-21 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
US8003649B2 (en) 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
KR101610415B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
CN101537006B (zh) * 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) * 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JP5390610B2 (ja) * 2008-07-25 2014-01-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
US20120028988A1 (en) * 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
ZA201100437B (en) 2011-09-28
PT2285811E (pt) 2013-03-05
US20110092498A1 (en) 2011-04-21
CN102066378B (zh) 2014-04-16
MX2010013649A (es) 2010-12-21
WO2009152920A1 (de) 2009-12-23
BRPI0915417A2 (pt) 2015-11-03
US8497266B2 (en) 2013-07-30
AR072860A1 (es) 2010-09-29
KR20110031329A (ko) 2011-03-25
KR101661777B1 (ko) 2016-09-30
EP2285811A1 (de) 2011-02-23
CA2728194C (en) 2016-11-29
IL210063A0 (en) 2011-02-28
DE102008028905A1 (de) 2009-12-24
JP5662311B2 (ja) 2015-01-28
EA201100031A1 (ru) 2011-08-30
BRPI0915417B1 (pt) 2020-02-11
PL2285811T3 (pl) 2013-04-30
EA019534B1 (ru) 2014-04-30
ES2400117T3 (es) 2013-04-05
EP2285811B1 (de) 2012-12-05
AU2009259764A1 (en) 2009-12-23
CN102066378A (zh) 2011-05-18
AU2009259764B2 (en) 2013-09-26
CA2728194A1 (en) 2009-12-23
JP2011524385A (ja) 2011-09-01
DK2285811T3 (da) 2013-03-11
IL210063A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
BRPI0915417B8 (pt) derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20084435L (no) C-MET proteinkinaseinhibitorer
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
BRPI0919873A2 (pt) composto de pirazol[1,5-a]pirimidina substituídos como inibidores da quinase trk
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
NI201000143A (es) Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a] pirimidinas, procedimientos para su preparación y usos de los mismos.
BR112012010041A2 (pt) derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
ECSP109953A (es) Derivados de piridazinona
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CL2012001180A1 (es) Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EA200901608A1 (ru) Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus
CR20120164A (es) Compuestos de pirrolo (2,3-d) pirimidina
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
EA201100966A1 (ru) Производные пиридазинона
CL2008003578A1 (es) Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc
ATE542814T1 (de) Pyrazinkinaseinhibitoren
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
BRPI0911161B8 (pt) derivados de piridazinona e seu processo de preparação
NZ630580A (en) 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.